Rare
Resolve.
- X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
- X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
- X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union